Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Ermenegildo Zegna N.V. Ordinary Shares (ZGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Ermenegildo Zegna N.V. Ordinary Shares — how do they compare? Vertex Pharmaceuticals Incorporated trades at $504.96 (market cap $122.98B), while Ermenegildo Zegna N.V. Ordinary Shares trades at $12.8 (market cap $3.48B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 35.3× Ermenegildo Zegna N.V. Ordinary Shares's market cap, and Ermenegildo Zegna N.V. Ordinary Shares pays a 1.06% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vertex Pharmaceuticals Incorporated for 120 Days and Ermenegildo Zegna N.V. Ordinary Shares for 0 Days on average.
| VRTX | ZGN | |
|---|---|---|
Market Cap | $122.98B | $3.48B |
Volume | 1,155,743 | 1,076,161 |
Sector | Health | Consumer Cyclical |
52-Week High | $557.96 | $15.25 |
52-Week Low | $407.90 | $8.69 |
Typical Hold Time | 120 Days | 0 Days |
Enterprise Value | $117.11B | $4.43B |
Dividend Yield | — | 1.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $498.50, down 1.68% amid mixed technical signals. The stock shows strong fundamentals with $12B revenue, 35% net margins, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Technical indicators show bearish momentum with support at $496 and resistance at $512.
Outlook remains positive with 86% analyst buy ratings and $573.50 price target. Key risks include clinical trial outcomes and competitive pressures. The company's expanding pipeline and profitability provide upside potential, though near-term volatility may persist around key technical levels.
ZGN trades at $12.94, up 2.7% with a neutral technical outlook. The stock shows mixed fundamentals with a high P/E of 38.5 but strong gross margins of 67.58%. Recent earnings beat expectations in three of the last four quarters, though Q2 2026 missed estimates. Analyst consensus is bullish with a $14.12 price target and 66.7% buy ratings. Revenue growth continues with 2025 reaching $1.92B, though net margins compressed to 3.98%.
ZGN presents a growth opportunity with expanding DTC momentum and margin potential, but faces valuation concerns and competitive pressures. The stock's upside depends on sustained earnings growth and successful execution of the retail-first strategy amidst fashion sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Ermenegildo Zegna N.V. Ordinary Shares
Ermenegildo Zegna N.V. is a luxury fashion group whose brands include Zegna, Thom Browne, and Tom Ford Fashion. The company operates a vertically integrated supply chain, sourcing wool from its own Australian farm through to finished garment production.
Read more on ZGN →
